Equities analysts expect that ABIOMED, Inc. (NASDAQ:ABMD) will report earnings of $0.73 per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for ABIOMED’s earnings, with estimates ranging from $0.68 to $0.78. ABIOMED reported earnings per share of $0.44 during the same quarter last year, which indicates a positive year-over-year growth rate of 65.9%. The business is scheduled to announce its next earnings results on Thursday, October 25th.
According to Zacks, analysts expect that ABIOMED will report full year earnings of $4.57 per share for the current year, with EPS estimates ranging from $4.43 to $4.70. For the next fiscal year, analysts forecast that the company will report earnings of $4.73 per share, with EPS estimates ranging from $4.50 to $5.36. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for ABIOMED.
ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, July 26th. The medical equipment provider reported $1.95 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.80 by $1.15. ABIOMED had a return on equity of 18.91% and a net margin of 25.71%. The business had revenue of $180.01 million for the quarter, compared to the consensus estimate of $173.87 million. During the same period last year, the business earned $0.82 EPS. The firm’s revenue was up 35.9% compared to the same quarter last year.
Several research analysts have commented on the company. BidaskClub downgraded ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 18th. Zacks Investment Research downgraded ABIOMED from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. Piper Jaffray Companies lifted their price target on ABIOMED from $360.00 to $480.00 and gave the stock an “overweight” rating in a research report on Friday, June 22nd. ValuEngine downgraded ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 18th. Finally, Jefferies Financial Group lifted their price target on ABIOMED to $460.00 and gave the stock a “buy” rating in a research report on Tuesday, May 29th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $374.88.
Shares of NASDAQ ABMD opened at $395.67 on Friday. The company has a market capitalization of $17.63 billion, a price-to-earnings ratio of 144.46, a price-to-earnings-growth ratio of 4.20 and a beta of -0.07. ABIOMED has a 12 month low of $155.57 and a 12 month high of $450.93.
In other news, Chairman Michael R. Minogue sold 105,000 shares of the business’s stock in a transaction that occurred on Thursday, June 21st. The stock was sold at an average price of $439.69, for a total transaction of $46,167,450.00. Following the sale, the chairman now directly owns 481,150 shares in the company, valued at $211,556,843.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO David M. Weber sold 19,282 shares of the business’s stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $356.77, for a total value of $6,879,239.14. Following the sale, the chief operating officer now owns 167,124 shares in the company, valued at $59,624,829.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 128,722 shares of company stock worth $54,800,489. Company insiders own 3.50% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ABMD. WealthTrust Fairport LLC bought a new stake in shares of ABIOMED during the first quarter valued at approximately $145,000. Cerebellum GP LLC bought a new stake in shares of ABIOMED during the second quarter valued at approximately $151,000. Dupont Capital Management Corp bought a new stake in shares of ABIOMED during the first quarter valued at approximately $161,000. OLD Mutual Customised Solutions Proprietary Ltd. bought a new stake in shares of ABIOMED during the second quarter valued at approximately $164,000. Finally, Rampart Investment Management Company LLC bought a new stake in shares of ABIOMED during the second quarter valued at approximately $175,000. Institutional investors and hedge funds own 86.23% of the company’s stock.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Further Reading: Are Wall Street analysts’ stock ratings worth following?
Get a free copy of the Zacks research report on ABIOMED (ABMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.